131 related articles for article (PubMed ID: 33610444)
21. Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.
Drangsholt S; Walter D; Ciprut S; Lepor A; Sedlander E; Curnyn C; Loeb S; Malloy P; Winn AN; Makarov DV
Urol Oncol; 2019 Feb; 37(2):145-149. PubMed ID: 30578160
[TBL] [Abstract][Full Text] [Related]
22. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
[TBL] [Abstract][Full Text] [Related]
23. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
Kulkarni SC; Sundaram PS; Padma S
Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
[TBL] [Abstract][Full Text] [Related]
24. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR.
Rosenkrantz AB; Verma S; Choyke P; Eberhardt SC; Eggener SE; Gaitonde K; Haider MA; Margolis DJ; Marks LS; Pinto P; Sonn GA; Taneja SS
J Urol; 2016 Dec; 196(6):1613-1618. PubMed ID: 27320841
[TBL] [Abstract][Full Text] [Related]
25. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.
Briganti A; Abdollah F; Nini A; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Passoni NM; Salonia A; Colombo R; Freschi M; Rigatti P; Montorsi F
Eur Urol; 2012 Jun; 61(6):1132-8. PubMed ID: 22099610
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer on computed tomography: A direct comparison with multi-parametric magnetic resonance imaging and tissue pathology.
Jia JB; Houshyar R; Verma S; Uchio E; Lall C
Eur J Radiol; 2016 Jan; 85(1):261-267. PubMed ID: 26526901
[TBL] [Abstract][Full Text] [Related]
27. Do patients who undergo multiparametric MRI for prostate cancer benefit from additional staging imaging? Results from a statewide collaborative.
Eyrich NW; Tosoian JJ; Drobish J; Montie JE; Qi J; Kim T; Noyes SL; Moriarity AK; Lane BR;
Urol Oncol; 2020 Jul; 38(7):636.e13-636.e19. PubMed ID: 32067844
[TBL] [Abstract][Full Text] [Related]
28. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
29. Imaging and Management of Prostate Cancer.
Surasi DSS; Chapin B; Tang C; Ravizzini G; Bathala TK
Semin Ultrasound CT MR; 2020 Apr; 41(2):207-221. PubMed ID: 32446432
[TBL] [Abstract][Full Text] [Related]
30. Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients.
Xie M; Gao XS; Ma MW; Gu XB; Li HZ; Lyu F; Bai Y; Chen JY; Ren XY; Liu MZ
Front Oncol; 2021; 11():646073. PubMed ID: 33928035
[TBL] [Abstract][Full Text] [Related]
31. The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer.
Ottosson F; Baco E; Lauritzen PM; Rud E
Eur Radiol; 2021 May; 31(5):2747-2753. PubMed ID: 33141299
[TBL] [Abstract][Full Text] [Related]
32. Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database.
Kindrick AV; Grossfeld GD; Stier DM; Flanders SC; Henning JM; Carroll PR
J Urol; 1998 Dec; 160(6 Pt 1):2102-6. PubMed ID: 9817332
[TBL] [Abstract][Full Text] [Related]
33. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
34. Preoperative staging of rectal cancer: pelvic MRI plus abdomen and pelvic CT. Does extrahepatic abdomen imaging matter? A case for routine thoracic CT.
Adeyemo D; Hutchinson R
Colorectal Dis; 2009 Mar; 11(3):259-63. PubMed ID: 18513197
[TBL] [Abstract][Full Text] [Related]
35. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
Pasoglou V; Larbi A; Collette L; Annet L; Jamar F; Machiels JP; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
Prostate; 2014 May; 74(5):469-77. PubMed ID: 24375774
[TBL] [Abstract][Full Text] [Related]
36. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
[TBL] [Abstract][Full Text] [Related]
37. The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report.
Belmonte M; Saia G; Zugni F; Alessi S; Colombo A; Summers PE; Luzzago S; Marvaso G; Musi G; De Cobelli O; Jereczek-Fossa BA; Petralia G
Acta Biomed; 2021 Sep; 92(4):e2021214. PubMed ID: 34487080
[TBL] [Abstract][Full Text] [Related]
38.
Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
[TBL] [Abstract][Full Text] [Related]
39. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
40. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
Salami SS; Vira MA; Turkbey B; Fakhoury M; Yaskiv O; Villani R; Ben-Levi E; Rastinehad AR
Cancer; 2014 Sep; 120(18):2876-82. PubMed ID: 24917122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
